Kuang Fei Li, Curtin Bryan F, Alao Hawwa, Piligian Brent, Berry Alexis, Holland-Thomas Nicole, Powers Astin, Quezado Martha, Lumbard Keith, Fay Michael P, Klion Amy D, Kumar Sheila, Khoury Paneez
Laboratory of Parasitic Diseases, NIAID, Bethesda, Md; Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, Ill.
Digestive Diseases Branch, NIDDK, National Institutes of Health, Bethesda, Md.
J Allergy Clin Immunol Pract. 2020 Sep;8(8):2718-2726.e2. doi: 10.1016/j.jaip.2020.04.025. Epub 2020 Apr 25.
Eosinophilic gastrointestinal diseases (EGIDs) are defined by marked eosinophilia in the gastrointestinal (GI) tract resulting in a wide variety of GI symptoms. When accompanied by blood hypereosinophilia (HE; absolute eosinophil count ≥1500/mm), EGID can occur as an isolated GI disorder (hypereosinophilic syndrome [HES]/EGID overlap) or as part of a multisystem hypereosinophilic syndrome (Multisystem HES).
To describe the GI disease of patients categorized as those with HES/EGID overlap versus those with Multisystem HES.
Consecutively enrolled patients on a natural history protocol to study eosinophilia with biopsy-proven EGID involving the esophagus, stomach, small-bowel, and/or colon were evaluated for clinical, histopathologic, and endoscopic features by retrospective chart review.
Among the 56 patients with EGID and HE, 34 were categorized as HES/EGID overlap and 22 as Multisystem HES. Demographics, GI symptoms, and associated comorbidities were similar between the 2 groups. Multisegment GI eosinophilia was present in 20 of 30 (67%) patients who underwent tissue sampling of all 4 GI segments. Tissue eosinophilia in all 4 GI segments was found in 5 of 30 (17%) patients. Dietary therapy was more common in patients with HES/EGID overlap (65% vs 23%, P = .0028). Patients with Multisystem HES were more likely to receive glucocorticoids (100% vs 79%, P = .0349) and nonglucocorticoid systemic therapies (77% vs 38%, P = .0061). One-third (8 of 22) of patients with Multisystem HES presented with isolated GI symptoms before developing extraintestinal manifestations at a median of 1 year (range, 0.25-15 years).
There are striking clinical similarities between patients with Multisystem HES and those with HES/EGID overlap, despite differing treatment approaches. Moreover, Multisystem HES can present with isolated GI involvement. Larger prospective studies are needed to confirm these findings.
嗜酸性粒细胞性胃肠疾病(EGIDs)的定义是胃肠道(GI)中显著的嗜酸性粒细胞增多,导致多种胃肠道症状。当伴有血液嗜酸性粒细胞增多(HE;绝对嗜酸性粒细胞计数≥1500/mm)时,EGID可作为一种孤立的胃肠道疾病(嗜酸性粒细胞增多综合征[HES]/EGID重叠)出现,或作为多系统嗜酸性粒细胞增多综合征(多系统HES)的一部分出现。
描述归类为HES/EGID重叠患者与多系统HES患者的胃肠道疾病情况。
通过回顾性病历审查,对连续纳入自然病史方案以研究嗜酸性粒细胞增多且经活检证实患有涉及食管、胃、小肠和/或结肠的EGID的患者进行临床、组织病理学和内镜特征评估。
在56例患有EGID和HE的患者中,34例归类为HES/EGID重叠,22例归类为多系统HES。两组患者的人口统计学、胃肠道症状和相关合并症相似。在对所有4个胃肠道节段进行组织采样的30例患者中,20例(67%)存在多节段胃肠道嗜酸性粒细胞增多。30例患者中有5例(17%)在所有4个胃肠道节段均发现组织嗜酸性粒细胞增多。饮食疗法在HES/EGID重叠患者中更为常见(65%对23%,P = 0.0028)。多系统HES患者更有可能接受糖皮质激素治疗(100%对79%,P = 0.0349)和非糖皮质激素全身治疗(77%对38%,P = 0.0061)。多系统HES患者中有三分之一(22例中的8例)在出现肠外表现之前出现孤立的胃肠道症状,中位时间为1年(范围为0.25 - 15年)。
尽管治疗方法不同,但多系统HES患者与HES/EGID重叠患者在临床上有显著相似之处。此外,多系统HES可表现为孤立的胃肠道受累。需要更大规模的前瞻性研究来证实这些发现。